Page last updated: 2024-11-08

succinobucol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

succinobucol: monosuccinic acid ester of probucol; a metabolically stable modification of probucol, an equipotent antioxidant to probucol but is pharmacologically distinct [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID216325
CHEMBL ID83626
CHEBI ID177810
SCHEMBL ID347492
MeSH IDM0497767

Synonyms (51)

Synonym
CHEMBL83626 ,
CHEBI:177810
4-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulanylpropan-2-ylsulanyl]phenoxy]-4-oxobutanoic acid
agz-1067
agi-1067
succinobucol
216167-82-7
succinobucol (usan)
D06648
succinic acid mono-{2,6-di-tert-butyl-4-[1-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-1-methyl-ethylsulfanyl]-phenyl} ester
bdbm50117525
probucol monosuccinate
4-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]-4-oxobutanoic acid
probucol monosuccinae
agi1067
4-(4-((1-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)sulfanyl)-1-methylethyl)sulfanyl)-2,6-bis(1,1-dimethylethyl)phenoxy)-4-oxobutanoic acid
butanedioic acid, mono(4-((1-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)-1-methylethyl)thio)-2,6-bis(1,1-dimethylethyl)phenyl) ester
succinobucol [usan:inn]
unii-j1j54v24r4
j1j54v24r4 ,
agi 1067
FT-0674682
butanedioic acid,1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]ester
succinobucol [inn]
succinobucol [usan]
succinobucol [mi]
S6420
DB05399
SCHEMBL347492
CS-7896
4-(2,6-di-tert-butyl-4-((2-((3,5-di-tert-butyl-4-hydroxyphenyl)thio)propan-2-yl)thio)phenoxy)-4-oxobutanoic acid
DTXSID10176003
AKOS030254650
J-014180
succinobucolagi 1067)
HY-14937
BS-16625
Q27095589
mfcd08690469
BCP31601
agi-1067; agi-1067; agi1067; probucol monosuccinate
nsc810340
nsc-810340
HMS3746A21
agi-1067;probucol monosuccinate
SC5126
agi 10674
EX-A5058
AC-36902
4-(2,6-di-tert-butyl-4-((2-((3,5-di-tert-butyl-4-hydroxyphenyl)thio)propan-2-yl)thio)phenoxy)-4-oxobutanoicacid
c35h52o5s2

Research Excerpts

Overview

Succinobucol is a novel derivative of probucol with improved antioxidant and anti-inflammatory properties.

ExcerptReferenceRelevance
"Succinobucol is a novel derivative of probucol with improved antioxidant and anti-inflammatory properties."( Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model.
Agbani, EO; Behnisch, B; Czudaj, P; Kennedy, S; McCormick, C; McPhaden, A; Mullen, A; Oldroyd, KG; Wadsworth, RM; Watt, J, 2013
)
2.55

Treatment

ExcerptReferenceRelevance
"Succinobucol pretreatment (6 days) significantly prevented 3-NP-induced loss of cellular viability, generation of reactive oxygen species, and decrease of ΔΨm."( Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity.
Braga, AL; Colle, D; de Bem, AF; Engel, DF; Farina, M; Godoi, M; Hartwig, JM; Santos, DB, 2016
)
2.6

Bioavailability

ExcerptReferenceRelevance
" AGI-1067 is the metabolically stable monosuccinic acid ester of probucol, and a potent phenolic antioxidant representing a novel class of orally bioavailable compounds termed vascular protectants."( AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Eisert, C; Malinin, A; Ong, S; Serebruany, VL, 2007
)
0.34
"Synthesis, detailed structural characterization (X-ray, NMR, MS, IR, elemental analysis), and studies of toxicity, antioxidant activity and bioavailability of unique potent anti-atherosclerotic succinobucol-steroid conjugates are reported."( Succinobucol's new coat--conjugation with steroids to alter its drug effect and bioavailability.
Buřičová, L; Drašar, P; Galandáková, A; Horníček, J; Ikonen, S; Jurček, O; Kolehmainen, ET; Ulrichová, J; Wimmer, Z; Wimmerová, M, 2011
)
2
" Furthermore, the oral bioavailability of SCB was greatly improved about 13-fold by SN, and the biodistribution in major organs was evidently enhanced."( Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression.
Cao, H; Chen, L; Gu, W; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z; Zhao, S, 2015
)
0.65

Dosage Studied

ExcerptRelevanceReference
"02 for the dose-response relationship; P< or =0."( Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L, 2003
)
0.32
" These data need to be confirmed in subjects receiving orally dosed AGI-1067 to be clinically relevant."( The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
Malinin, A; Scott, R; Serebruany, V, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vascular cell adhesion protein 1Homo sapiens (human)IC50 (µMol)6.00006.00006.50007.0000AID216494
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
response to hypoxiaVascular cell adhesion protein 1Homo sapiens (human)
chronic inflammatory responseVascular cell adhesion protein 1Homo sapiens (human)
inflammatory responseVascular cell adhesion protein 1Homo sapiens (human)
cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesVascular cell adhesion protein 1Homo sapiens (human)
leukocyte cell-cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
cell-matrix adhesionVascular cell adhesion protein 1Homo sapiens (human)
response to nutrientVascular cell adhesion protein 1Homo sapiens (human)
amine metabolic processVascular cell adhesion protein 1Homo sapiens (human)
response to zinc ionVascular cell adhesion protein 1Homo sapiens (human)
response to ionizing radiationVascular cell adhesion protein 1Homo sapiens (human)
membrane to membrane dockingVascular cell adhesion protein 1Homo sapiens (human)
B cell differentiationVascular cell adhesion protein 1Homo sapiens (human)
response to lipopolysaccharideVascular cell adhesion protein 1Homo sapiens (human)
cell-cell adhesion mediated by integrinVascular cell adhesion protein 1Homo sapiens (human)
heterotypic cell-cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
response to nicotineVascular cell adhesion protein 1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular cell adhesion protein 1Homo sapiens (human)
positive regulation of T cell proliferationVascular cell adhesion protein 1Homo sapiens (human)
response to ethanolVascular cell adhesion protein 1Homo sapiens (human)
leukocyte tethering or rollingVascular cell adhesion protein 1Homo sapiens (human)
cell chemotaxisVascular cell adhesion protein 1Homo sapiens (human)
innervationVascular cell adhesion protein 1Homo sapiens (human)
cardiac neuron differentiationVascular cell adhesion protein 1Homo sapiens (human)
cellular response to tumor necrosis factorVascular cell adhesion protein 1Homo sapiens (human)
cellular response to amyloid-betaVascular cell adhesion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
integrin bindingVascular cell adhesion protein 1Homo sapiens (human)
primary amine oxidase activityVascular cell adhesion protein 1Homo sapiens (human)
cell adhesion molecule bindingVascular cell adhesion protein 1Homo sapiens (human)
cell adhesion mediator activityVascular cell adhesion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
podosomeVascular cell adhesion protein 1Homo sapiens (human)
extracellular spaceVascular cell adhesion protein 1Homo sapiens (human)
early endosomeVascular cell adhesion protein 1Homo sapiens (human)
endoplasmic reticulumVascular cell adhesion protein 1Homo sapiens (human)
Golgi apparatusVascular cell adhesion protein 1Homo sapiens (human)
plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
microvillusVascular cell adhesion protein 1Homo sapiens (human)
external side of plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
cell surfaceVascular cell adhesion protein 1Homo sapiens (human)
filopodiumVascular cell adhesion protein 1Homo sapiens (human)
sarcolemmaVascular cell adhesion protein 1Homo sapiens (human)
apical part of cellVascular cell adhesion protein 1Homo sapiens (human)
extracellular exosomeVascular cell adhesion protein 1Homo sapiens (human)
alpha9-beta1 integrin-vascular cell adhesion molecule-1 complexVascular cell adhesion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID224019Inhibition of progression of atherosclerosis in aorta after oral dosing in cholesterol fed rabbits2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
AID135188Inhibition of progression of atherosclerosis in aorta after oral dosing in cholesterol fed LDL receptor knockout mice2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
AID216494Inhibition of TNF-alpha inducible Vascular cell adhesion molecule-1 expression.2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
AID202571Concentration required for 50% inhibition of TNF-alpha inducible Selectin E expression.2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
AID227564Inhibitory effect in preventing the oxidation of linoleic acid by 15-lipoxygenase at a concentration of 70 uM2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
AID281899Inhibition of TNF-alpha-stimulated VCAM1 expression in endothelial cells2004Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
AID89971Inhibition of proliferation of human aortic smooth muscle cells at a concentration of 5 uM2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
AID104100Concentration required for 50% inhibition of TNF-alpha inducible MCP-1 expression.2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's33 (63.46)29.6817
2010's19 (36.54)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.58 (24.57)
Research Supply Index4.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (9.43%)5.53%
Reviews17 (32.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (58.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]